TransCode Therapeutics, Inc. Common Stock (RNAZ) is a publicly traded Healthcare sector company. As of May 21, 2026, RNAZ trades at $6.35 with a market cap of $5.66M and a P/E ratio of -0.12. RNAZ moved +0.00% today. Year to date, RNAZ is -17.43%; over the trailing twelve months it is -25.12%. Its 52-week range spans $5.56 to $739.20. Rallies surfaces RNAZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
RNAZ financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RNAZ recently traded at $6.35. Market cap is $5.66M. P/E ratio is -0.12. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $6.35 |
| Market Cap | $5.66M |
| P/E Ratio | -0.12 |
| EPS | $-52.59 |
| Dividend Yield | 0.00% |
| 52-Week High | $739.20 |
| 52-Week Low | $5.56 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-34.66M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0 | $-34.66M | $-52.59 |
| 2024 | $0 | $-16.75M | $-47.14 |
| 2023 | $0 | $-18.55M | $-103.61 |
| 2022 | $0 | $-17.56M | $-1.35 |
RNAZ analyst coverage data. Average price target: $0.00.